ClinicalTrials.gg
RecruitingNCT05142683CARIBOU-2Updated Aug 20, 2026

Effectiveness of an Integrated Care Pathway for Depression: Cluster Randomized Controlled Trial

An interventional study of Treatment As Usual and CARIBOU-2 in Major Depressive Disorder, sponsored by Centre for Addiction and Mental Health. Recruiting at 1 site in Canada. Open to participants aged 13 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Centre for Addiction and Mental Health · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
13 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 48 studies in Depressive Disorder, Major by Centre for Addiction and Mental Health — 10 open to participants now, 13 under way, none of them phase 3. Depressive Disorder, Major · Centre for Addiction and Mental Health.

Planned enrollment
3rd of 44
300 · median 72
Started
2022
with 3 others
No phase
36 of 48
6 open now
Primary completion
2027-09
later than 8 of 12 live
Registered
37th of 48
by date

Among the 48 studies in Depressive Disorder, Major by Centre for Addiction and Mental Health, this one is the 3rd largest by planned enrollment of the 44 interventional ones that give a count, is one of 4 that started in 2022, is one of 36 with no phase, reaches primary completion later than 8 of the 12 other live ones, and was the 37th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

10 of the 48 studies in Depressive Disorder, Major by Centre for Addiction and Mental Health are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 13 Years to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Depressive Disorder, Major by Centre for Addiction and Mental Health, or all of them as a file.
02

Study summary

This is a quasi-experimental, multi-site cluster controlled clinical trial design with two intervention arms--Treatment As Usual (TAU) and an Integrated Care Pathway (ICP). Eligible participants are between the ages of 13 and 18, who present to community mental health agencies with depressive symptoms as the primary concern. The primary clinical outcome of interest is the difference between treatment groups in the rate of change of depressive symptoms from baseline to 24-week endpoint as measured by the Mood and Feelings Questionnaire. The secondary outcomes include rate of change of functional improvement, as measured by the Childhood Anxiety and Depression Life Interference Scale, and caregiver-rated internalizing symptoms as rated by the Childhood Behaviour Checklist. This study will also be examining implementation outcomes such as feasibility, fidelity cost and acceptability.

Read the detailed description

Background: Depression is the leading cause of disability in adolescents and a potent risk factor for suicide. Evidence-based treatments are available; however, many clinics do not provide guidelines-based treatments. Integrated Care Pathways (ICPs) are treatment algorithms based on the highest quality practice guidelines intended to facilitate the delivery of evidence-based treatment at the clinic level. Our group has already tested the feasibility of ICP for adolescent depression at an academic setting. There is still uncertainty regarding whether ICPs lead to improved outcomes in depression in adolescents in community settings relative to typical care.

Objective: The current study aim is to test the effectiveness of an ICP for depression in adolescence, called the CARIBOU-2 intervention, versus treatment-as-usual (TAU) in community settings. This study will also examine important implementation outcomes.

Method: The primary participants are adolescents (Up to N=150), between the ages of 13 to 18 with depressive symptoms, presenting to one of the participating sites. Through a quasi-experimental, multi-site cluster controlled clinical trial design, sites began in the TAU condition and transitioned to the ICP condition once local enrollment to TAU has reached up to 25 participants. The primary clinical outcome of interest is the difference between treatment groups in the rate of change of depressive symptoms from baseline to 24-week endpoint as measured by the Mood and Feelings Questionnaire. Secondary outcomes include rate of change of functional improvement, as measured by the Childhood Anxiety and Depression Life Interference Scale, and caregiver-rated internalizing symptoms as rated by the Childhood Behaviour Checklist. This study will also be examining the following implementation outcomes: feasibility, fidelity cost and acceptability. Implementation will also be assessed at three additional sites through a light-touch evaluation conducted several months after training and implementation of the pathway, focusing on clinicians' perspectives and experiences.

Statistical Analyses:

Descriptive data analysis will be first conducted to examine distribution of collected measures and evaluate whether there are significant differences across arms of assigned sites. Generalized linear mixed-effects model will be the primary analytic tool for evaluating whether the CARIBOU-2 intervention is more effective than TAU for adolescents with depression presenting to care with regards to improvement of depressive symptoms, self-reported functioning, caregiver-reported internalizing psychopathology, and suicidal ideation and behaviours. Time, treatment assignment and their interactions will serve as the primary predictors for the analyses. As an example, if we let Y_ijt to denote a continuous outcome of the j-th participant of the i-th site measured at time t, a linear model for Y_ijt will look like the following:

Y_ijt=β_0+〖b_(0,ij)+b_(1,i)+β〗_1 t+β_2 〖Group〗_(i,t)+β_3 Group_it*t+〖β_4 X_ijt+ϵ〗_ijt

of which 〖Group〗_(i,t) denotes the treatment assignment of the i-th site at time t, X_ijt, additional covariates, b_(0,ij) and b_(1,i), random effects at individual and site levels respectively, ϵ_( ijt), unexplained random error, and β's, regression coefficients. For sensitivity analyses, we will explore the use of the piecewise model to model the time trend differently. We will adopt the intention-to-treat approach in general and use multiple imputation methods as the primary missing data strategy. In our pilot study, we have collected \~85% of expected longitudinal data points on the MFQ (primary clinical outcome), adjusting for attrition. Sensitivity analysis will be conducted to evaluate the impact of non-random missing and robust regression method will be used instead when the impact is high. SAS 9.4 will be our go-to software package for this project.

Relevance: Should our results be consistent with our hypotheses, systematic implementation of the CARIBOU-2 intervention to other community mental health agencies and hospitals would be indicated.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Adolescents
  • Integrated Care Pathway
  • Depression
  • Measurement Based Care
  • Implementation
04

Who can participate

Ages eligible
13 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Youth is aged 13 to 18 years, inclusive.
  • Youth and/or their caregiver is expressing that 'depression" (or some synonym) is a concern.
  • Clinician agrees that depressive symptoms are a treatment target.
  • Mood and Feelings Questionnaire score is ≥22 at two sequential visits (screening and baseline assessment).
  • Youth must be new to the site (in past 3 months) or have a period of no treatment for 3 months

Exclusion criteria

Exclusion Criteria:

  • Known or highly suspected presentations of psychotic symptoms that are persistent, affect functioning, and have observable effects on behaviour.
  • Severe substance use disorder, bipolar disorder, autism spectrum disorder or intellectual disability, severe eating disorder, imminent risk of suicide requiring hospitalization as per judgment of the assessing clinician.
  • Inability to provide to the study for any reason
  • Youth currently in Day Treatment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Active comparator
    Treatment as Usual

    Study involvement for all sites will begin in the TAU condition, which is the typical treatment at the participating community mental health agency. A range of treatments observed in our previous survey of sites will be on offer in these agencies, depending on the preferences and context of the local agency. In typical TAU in community mental health agencies, depressive symptoms and function are not systematically monitored via standardized rating scales. TAU may or may not include referral to psychotherapy and/or parent support. There are no prompts to prescribe specific medications, and/or internal and external referrals to treatment and other services, guided by local service standards.

    Other: Treatment As Usual

  • Experimental
    CARIBOU-2

    After the CARIBOU-1 pilot study, the Principal Investigator revised the ICP to render it more applicable to community settings as well as offer a second-line psychotherapy ("Brief Psychosocial Intervention") for youth who do not engage with, or respond to, cognitive-behavioural therapy. The revised version is called the CARIBOU-2 intervention. The current iteration of the pathway involves a series of steps: (1) structured assessment, including safety assessment; (2) education on depression, sleep, exercise, and diet; (3) psychotherapy (with 1st line Cognitive Behavioural Therapy, 2nd line "Brief Psychosocial Intervention"); (4) a caregiver structured support group; (5) medication options (1st line fluoxetine, 2nd line sertraline); (6) "team reviews" every four weeks, (meeting with the youth and involved clinicians to review measures and discuss treatment changes); and, (7) discharge and follow-up planning.

    Other: CARIBOU-2

Interventions

  • OtherTreatment As Usual

    Various typical interventions for adolescents with depression.

  • OtherCARIBOU-2

    Integrated Care Pathway intervention for adolescents with depression.

06

What researchers measure

Primary outcomes

  1. The Mood and Feelings Questionnaire (MFQ) child, long version

    The MFQ is a 33-item self-report measure for youth regarding depressive symptoms experienced over the prior 2 weeks. It was specifically recommended in the NICE guideline, given its strong psychometric properties; namely, it has high discriminatory ability in adolescents, good internal consistency (α=0.92-0.94) and good test-retest reliability (Pearson's r=0.78). It has also been used in a large trial of psychotherapy with adolescents where it was sensitive to change.

    Time frame: Change from baseline to 24 weeks

Secondary outcomes

  1. The Child Behaviour Checklist (CBCL) - Parent Report Form

    A 118-item caregiver-rated measure assessing the youth's behaviour and general psychopathology. It is a widely used measure with known population norms. One-week test-retest reliability was found to be 0.80-0.94. Internal consistency is reported to be high; inter-rater reliability (e.g., between two parents) was found to be moderate to high (reference needed). All subscales will be used at baseline to describe general psychopathology. The internalizing broadband scale of the CBCL (i.e. anxious-depressed, depressed-withdrawn, and somatic subscales combined) will be measured longitudinally to get an impression of how the caregiver is observing any changes in mood or anxiety with treatment.

    Time frame: Baseline to 24-weeks

  2. Columbia Suicide Severity Rating Scale

    This measure contains items related self-injurious thoughts and behaviours. RAs rate 3 subscales: Suicidal Ideation Severity, Suicidal Behaviour (which includes suicide attempts and an item for non-suicidal self-injury that is recorded as distinct from suicidal behaviour), and Lethality.

    Time frame: Change from baseline to 24 weeks

  3. Depression Rating Scale

    This is an RA-rated 13-item subscale found in the Kiddie Schedule for Affective Disorders and Schizophrenia-Lifetime version used to assess for DSM-5 criteria of Major Depressive Disorder.

    Time frame: Change from baseline to 24 weeks

  4. Youth Quality of Life Scale Research Version

    This is a 41 item self-report scale measuring the broad array of constructs including sense of self-worth, quality of relationships, sense of agency and life satisfaction.

    Time frame: Change from baseline to 24 weeks

  5. Clinical Global Impression Scale - both the Improvement Subscale (CGI-I) and Severity Subscale (CGI-S)

    The CGI-I is a one-item assessment of the clinician's sense of change in a patient's symptom burden and overall functioning. Seven response options are available with scores ranging from 1 through 7: "very much improved", "much improved", "a little improved", "no change", "a little worse", "much worse", and "very much worse". In a previous study, the CGI-I has demonstrated good inter-rater reliability at identifying responders - defined as cases rated to be "very much improved" or "much improved" (Asarnow, Emslie, Clarke et al. 2009). This measure is used broadly across RCTs for adolescent depression (Courtney et al, 2021) and will be used to select the clinical significance of our finding and render findings comparable to other studies.

    Time frame: Baseline to 24-weeks

  6. Health and Social Service Utilization

    This is a 10-item, self-report questionnaire that collects data regarding services and medications used by the patient.

    Time frame: Change from baseline to 24 weeks

  7. Ontario Perception of Care Tool for Mental Health and Addictions

    Two versions of this tool were developed by CAMH (one for registered patients and one for family members of clients) and typically consists of 38 items on a Likert scale. It standardizes how substance use, mental health, and concurrent disorder services obtain client perception of care feedback.

    Time frame: Change from baseline to 24 weeks

  8. Adolescent Alcohol and Drug Involvement Scale Grid

    This scale is used for adolescent substance abuse frequency. It includes both alcohol and other drug abuse.

    Time frame: Change from baseline to 24 weeks

  9. Cognitive Behavioural Therapy Skills Questionnaire

    This 16-item measure utilizing a Likert scale from 1 (I don't do this) to 5 (I always do this) assess an individual's cognitive restructuring and behavioral activation skills.

    Time frame: Change from baseline to 24 weeks

  10. CollaboRATE

    This is a 3 item measure on a 5-point Likert Scale that measures the level of shared decision making in the clinical encounter from the patient's perspective, as part of assessing health care quality and provider performance.

    Time frame: Change from baseline to 24 weeks

  11. Nonsuicidal Self-Injury

    This measure comes from the Self-Injurious Thoughts and Behaviors Interview, which is a structured interview that assesses the presence, frequency, and characteristics of a wide range of self-injurious thoughts and behaviors, including suicidal ideation, suicide plans, suicide gestures, suicide attempts, and nonsuicidal self-injury (NSSI). The NSSI section has been adapted for the purposes of the study.

    Time frame: Change from baseline to 24 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Bennett K, Courtney D, Duda S, Henderson J, Szatmari P. An appraisal of the trustworthiness of practice guidelines for depression and anxiety in children and youth. Depress Anxiety. 2018 Jun;35(6):530-540. doi: 10.1002/da.22752. Epub 2018 Apr 26. PubMed 29697887 ↗
  • Courtney D, Bennett K, Henderson J, Darnay K, Battaglia M, Strauss J, Watson P, Szatmari P. A Way through the woods: Development of an integrated care pathway for adolescents with depression. Early Interv Psychiatry. 2020 Aug;14(4):486-494. doi: 10.1111/eip.12918. Epub 2019 Dec 27. PubMed 31883210 ↗
  • Courtney DB, Bennett K, Szatmari P. The Forest and the Trees: Evidence-Based Medicine in the Age of Information. J Am Acad Child Adolesc Psychiatry. 2019 Jan;58(1):8-15. doi: 10.1016/j.jaac.2018.06.035. PubMed 30577942 ↗
  • Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012 Mar;50(3):217-26. doi: 10.1097/MLR.0b013e3182408812. PubMed 22310560 ↗
  • Hytman L, Mansueto S, Chan JI, Kumar R, Nguyen ATP, Wang W, Krause KR, Monga S, Szatmari P, Courtney DB. Interrater Reliability and Measurement Error of the Children's Depression Rating Scale-Revised in Adolescents. JAACAP Open. 2025 Jun 20;3(4):1225-1235. doi: 10.1016/j.jaacop.2025.06.005. eCollection 2025 Dec. PubMed 41367969 ↗
  • de Oliveira C, Mason J, Amani B, Liddell G, Szatmari P, Henderson J, Courtney D. Protocol for the economic evaluation of the Care for Adolescents who Received Information 'Bout Outcomes, 2nd iteration (CARIBOU-2) non-randomised, cluster-controlled trial of an integrated care pathway for depression in adolescents. BMJ Open. 2025 May 15;15(5):e092541. doi: 10.1136/bmjopen-2024-092541. PubMed 40379352 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified research data from participants who have consented to share their study data for future unspecified research will be stored in CAMH's BrainHealth Databank (BHDB). The BHDB enables researchers to access and use these data for future research on mental health and related conditions, with the aim of advancing understanding and improving treatments and care. Any secondary use or analysis of the data will require appropriate ethics approval, as well as approval from the study sponsor and Principal Investigator.

Supporting information: Study protocol, Analytic code

Time frame: De-identified research data from participants who have consented to share their study data for future unspecified research will be stored in CAMH's BrainHealth Databank from the end of the study through 10 years after study completion (approximately 2028-2038).

Access criteria: Eligible de-identified research data will be stored in CAMH's BrainHealth Databank. Any secondary use or analysis of the data will require appropriate ethics approval, as well as approval from the study sponsor and/or Principal Investigator.

Data sharing details ↗ · www.camh.ca

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Sep 2027, 67 months after the start.

Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 67 months is above that.

Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2021
First posted
Dec 2, 2021
StartActual
Feb 1, 2022
Primary completionEst.
Sep 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05142683
Collaborators
Canadian Institutes of Health Research (CIHR), The Hospital for Sick Children
Responsible party
Sponsor
First posted
Dec 2, 2021
Start date
Feb 1, 2022
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Aug 20, 2026

Study contacts

Darren B Courtney, MD
Contact
dr.courtney.research@gmail.com
800-463-2338 ext. 30539
Eva Gonzalez Villanueva, Research Coordinator, MPH, MSSW, RSW
Contact
eva.gonzalezvillanueva@camh.ca
800-463-2338 ext. 30539
Darren B Courtney, MD
principal investigator · University of Toronto

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion